TABLE 1.

Clinical and demographic characteristics of recipients and kidney donors given for different age categories of recipients.

	18–39 years n = 242	40–55 years n = 277	>55 year n = 218	p-value
Median age recipient in years (IQR)	30 (25–35)	47 (43–51)	61 (57–65)
Median age donor in years (IQR)	46 (34–55)	46 (38–55)	54 (39–61)	<0.001
Recipient male/female ratio	48/52%	47/53%	45/55%	0.9
Deceased/living donor kidney	37%/63%	64%/36%	73%/27%	0.07
-DBD type*	92%	80%	81%
-DCD type*	8%	20%	19%	0.002
-Delayed graft function	59%	50%	40%	0.3
-Duration of delayed graft function median days (IQR)	12 (6–14)	10 (9–16)	15 (9–21)	0.3
Cold ischemia time in hours	9.8 ± 0.6	11.3 ± 0.6	11.7 ± 0.7	0.3
Retransplantation	23%	19%	11%	0.003
PRA at transplantation, means (SD)	10% (21.7)	8% (18.2)	5% (16.1)	<0.001
Total HLA mismatches, means (SD)	2.2 (1.4)	2.5 (1.6)	2.9 (1.6)	0.8
Follow-up in years, median (IQR)	14.6 (5.9–19.7)	14.9 (6.6–17.7)	11.2 (6.6–18.0)	<0.001
Recipients with anti-HLA DSA at time transplantation	24.5%	21.8%	18.8%	0.4
Induction therapy	15	24	18	0.9
- Anti-IL-2 receptor antibody	13	24	18
- T cell depleting antibody	2	0	0
Maintenance immune suppression				0.9
- Steroids	90.4%	92.2%	92.0%
- Tacrolimus/ciclosporin	60.3%/38.6%	59.3%/37.5%	65.9/32.0%
- MMF/azathioprine	69.7%/0.5%	75.6%/0.0%	70.7/0.0%
- Sirolimus	8.4%	7.5%	9.2%
- Other	4.5%	3.1%	3.2%

*Type of deceased donor, by brain death (DBD) or cardiac death (DCD), given as % of total deceased donor kidneys, PRA, panel reactive antibodies; DSA, donor specific antibodies; SD, standard deviation; IQR, interquartile range; P-values were calculated with Kruskal-Wallis H-test for comparing multiple independent samples.